Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 2, 2008, Pages 160-167

  Haley, Connie A ^a,b,c,d   Stephan, S ^a,b   Vossel, L F ^a   Sherfy, E A ^a   Laserson, K F ^c   Kainer, M A ^a  

^a TENNESSEE DEPARTMENT OF HEALTH   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NONE   (United States)

Author keywords

Adherence; Foreign born; Hepatotoxicity; Latent tuberculosis infection; Rifampicin

Indexed keywords

RIFAMPICIN;

ADULT; AGED; ANOREXIA; ARTICLE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HISPANIC; HUMAN; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS; URINE COLOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTITUBERCULAR; EMIGRANTS AND IMMIGRANTS; FEMALE; HISPANIC AMERICANS; HUMANS; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RIFAMPIN; RISK FACTORS; TREATMENT REFUSAL; TUBERCULOSIS, PULMONARY;

EID: 38949168816     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC, USA: National Academy Press, 2000.
2. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
3. Centers for Disease Control and Prevention. Controlling tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 2005; 54: 1-81.
4. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 17: 28-106.
5. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trail. Bull World Health Organ 1982; 60: 555-564.
6. Comstock G W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-850.
7. Dooley K E, Sterling T R. Treatment of latent tuberculosis infection: challenges and prospects. Clin Chest Med 2005; 26: 313-326.
8. Nolan C M, Goldberg S V, Buskin S E. Hepatotoxicity associated with isoniazid preventive therapy: a seven-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
9. LoBue P A, Moser K S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Resp Crit Care Med 2003; 168: 443-447.
10. Reichman L B, Lardizabal A, Hayden C H. Considering the role of four months rifampicin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2004; 170: 832-835.
11. Lecouer H F, Truffot-Pernot C, Grosset J H. Experimental short course preventive therapy of tuberculosis with rifampicin and pyrazinamide. Am Rev Respir Dis 1989; 140: 1189-1193.
12. Dhillon J, Dickinson J M, Sole K, et al. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampicin, isoniazid and pyrazinamide. Antimicrob Agents Chemother 1996; 40: 552-555.
13. Ji B, Truffot-Pernot C, Lacriox C, et al. Effectiveness of rifampicin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1541-1546.
14. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC Recommendations against the use of rifampicin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52: 735-739.
15. Priest D H, Vossel L F, Sherfy E A, Hoy D P, Haley C A. Use of intermittent rifampicin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis 2004; 39: 1764-1771.
16. Hong Kong Chest Service/Tuberculosis Research Centre; Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
17. Menzies D, Dion M, Rabinovitch B, Mannix S, Brassard P, Shwartzman K. Treatment completion and costs of a randomized trial of rifampicin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-449.
18. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2005. Atlanta, GA, USA: US Department of Health and Human Services, CDC, 2005.
19. Tennessee Department of Health. Epidemiological profile of reported tuberculosis in Tennessee, 2005. Nashville, TN, USA: Tennessee Department of Health, Communicable and Environmental Disease Services, 2007.
20. Tennessee Department of Health. The Hispanic Population in Tennessee, July 2004. Nashville, TN, USA: Tennessee Department of Health, Division of Health Statistics, 2004. http://www2.state.tn.us/health/statistics/PdfFiles/ TNHispanic00.pdf Accessed December 2007.
21. Tennessee Department of Health. Tuberculosis Elimination Guidelines, 2004. Nashville, TN, USA: Tennessee Department of Health, Communicable and Environmental Disease Services, 2004.
22. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
23. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman L B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampicin. Chest 2006; 130: 1712-1717.
24. Page K R, Sifakis F, Montes de Oca M, et al. Improved adherence and less toxicity with rifampicin vs. isoniazid for treatment of latent tuberculosis. Arch Intern Med 2006; 166: 1863-1870.
25. Polensky A, Farber H W, Gottleib D J, et al. Rifampicin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996; 154: 1473-1477.
26. Villarino M E, Ridzon R, Weismuller P C, et al. Rifampicin preventive therapy for tuberculosis infection. Am J Respir Crit Care Med 1997; 155: 1735-1738.
27. Bock N N, Metzger B S, Tapia J R, Blumberg H M. A tuberculosis screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999; 159: 295-300.
28. White M C, Tulsky J P, Goldenson J, Portillo C J, Kawamura L M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Int Med 2002; 162: 1044-1050.
29. Lobato M N, Reves R R, Jasmer R M, Grabau J C, Bock N N, Shang N and the 2RZ Study Group. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005; 127: 1296-1303.
30. White M C, Tulsky J P, Menendez E, Goldenson J, Kawamura L M. Incidence of TB in inmates with latent TB infection, 5-year follow-up. Am J Prev Med 2005; 29: 295-301.
31. Tulsky J P, White M C, Dawson C, Hoynes T M, Goldenson J, Schecter G. Screening for tuberculosis in jail and clinic follow-up after release. Am J Public Health 1998; 88: 223-226.
32. Nolan C M. Community-wide implementation of targeted testing for and treatment of latent tuberculosis infection. Clin Infect Dis 1999; 29: 880-887.
33. Marks S M, Taylor Z, Qualls N L, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162: 2033-2038.
34. D'Lugoff M I, Jones W, Kub J, et al. Tuberculosis screening in an at-risk immigrant Hispanic population in Baltimore City: An academic health center/local health department partnership. J Cult Divers 2002; 9: 79-85.
35. White M C, Tulsky J P, Reilly P, McIntosh H W, Hoynes T M, Goldenson J. A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. Int J Tuberc Lung Dis 1998; 2: 506-512.